Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375230 | 0.82 | AKR1C2 (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL184603 | 0.82 | AKR1C2 (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL29113264 | 0.80 | AKR1C2 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL29113267 | 0.80 | AKR1C2 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL29113270 | 0.80 | AKR1C2 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL942780 | 0.80 | AKR1C2 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL11025687 | 0.80 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL939981 | 0.80 | AKR1C2 (0.96) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL659333 | 0.80 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL29613154 | 0.80 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103992336-B | Oxa-or thia evodiamine anti-tumor derivant and preparation method thereof | 中国人民解放军第二军医大学 | 2017-01-04 | — | — | CN | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| US-4350692-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | AKR1C4 164/4885AKR1C3 345/4885AKR1C2 356/4885 |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | SERPINE1, SERPINC1, SERPINB1 | AKR1C4 374/4885AKR1C3 270/4885AKR1C2 530/4885 |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | AKR1C4 422/4885AKR1C3 302/4885AKR1C2 528/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | AKR1C4 1059/4885AKR1C3 1574/4885AKR1C2 1620/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | AKR1C4 211/4885AKR1C3 495/4885AKR1C2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.